Latest News and Press Releases

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Completed KP415 clinical and human abuse...

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, February 28, 2019, 4:30 p.m. ET CELEBRATION, Fla., Feb. 21, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc....

Patents Extend Across KemPharm’s Prodrug Portfolio, Including IP Protection for KP415 in Canada, Japan and Korea CELEBRATION, Fla., Jan. 29, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH),...

Posters include intranasal and oral HAP data for serdexmethylphenidate (SDX), as well as PK data for KP415 Intranasal HAP data selected to be presented during oral “data blitz session” ...

APADAZ® Now Approved in Three Dosage Strengths, Providing Greater Flexibility to Prescribers Through Additional Dosing Options CORALVILLE, Iowa, Jan. 07, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc....

CELEBRATION, Fla., Dec. 19, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today...

Findings suggest that SDX, a prodrug of d-methylphenidate, is unlikely to be attractive for intravenous abuse CELEBRATION, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a...

KP879 is being developed with serdexmethylphenidate, KemPharm’s prodrug of d-methylphenidate, to address a critical unmet need in the treatment of problematic stimulant abuse CELEBRATION, Fla.,...

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development Highlights: Announced positive topline results from KP415.E01 efficacy and safety trial...

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, November 8, 2018, 4:30 p.m. ET CORALVILLE, Iowa, Nov. 01, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc....